NEW YORK (GenomeWeb News) – Shares in Accelr8 plummeted nearly 30 percent today following news that Becton Dickinson has declined an option to license the company's rapid bacterial diagnostic system.

BD advised the company that it would decline an exclusive license option to the technology associated with an 18-month testing agreement it inked with Accelr8 in April 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.